Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Tirrell"


25 mentions found


watch nowLife expectancy in the U.S. is between three and five years lower than the average in other high-income countries — and the gap comes in part from misinformation, Food and Drug Administration Commissioner Dr. Robert Califf said. He said there's a need for better regulation, including "specific authorities at FDA, FTC and other areas" to root out misinformation. Food and Drug Administration Commissioner Robert Califf testifies before a Senate Health, Education, Labor, and Pensions hearing to examine an update on the ongoing Federal response to COVID-19, at the U.S. Capitol in Washington, U.S., June 16, 2022. The FDA commissioner spoke about multiple topics including efforts to cut drug prices, a priority for the Biden administration and lawmakers from both parties in Congress. Incentives for researchCaliff is also encouraging the drug industry to consider investments in neglected areas of research.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA commissioner says health misinformation is driving U.S. life expectancy downDr. Robert Califf says in an interview with CNBC that better regulation is needed to combat health misinformation that's costing Americans years of life. He also weighs in on what the agency can do about drug pricing, where he wants to see the drug industry focus more, and new drugs for obesity.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna says there are not enough cases to declare early success for its mRNA flu vaccineCNBC's Meg Tirrell reports on news from Moderna that it will delay results from its flu vaccine trials.
Pfizer 's CEO signed on to an industry letter in support of the Food and Drug Administration's authority to regulate drugs after a federal judge in Texas suspended the agency's approval of the abortion pill mifepristone. Albert Bourla was among the more than 200 pharmaceutical company executives who signed the letter after U.S. Judge Matthew Kacsmaryk's controversial ruling on Friday. Kacsmaryk sided with an anti-abortion group, arguing that the FDA rushed its approval process and violated federal standards. Kacsmaryk's decision conflicts with a ruling by a federal judge in Washington state. The dueling orders by two federal judges create a complicated legal standoff that could potentially escalate to the Supreme Court.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHow America's complex drug supply chain is creating vulnerability in the systemCNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss intensifying shortages in America for antibiotic prescriptions and generic drugs, the global consequences of local drug manufacturing disruptions, and the need for transparency in drug manufacturing.
Bridgebio shares surge on takeout target hopes
  + stars: | 2023-03-29 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBridgebio shares surge on takeout target hopesCNBC's Meg Tirrell joins 'Power Lunch' to report on Bridgebio's stock surge and pharma returns.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGeneric drugs are most likely to face shortages due to market failures in affordabilityCNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAntibiotics in short supply: U.S. drug shortages reach historic highHosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m. ET on CNBC. CNBC's Meg Tirrell reports on the antibiotic shortage hitting the U.S.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAntibiotics in short supply: U.S. drug shortages hit record levelCNBC’s Meg Tirrell joins ‘Closing Bell: Overtime’ to report on why there's a shortage of antibiotics in the U.S.
Regeneron's Dupixent shows promise as COPD treatment
  + stars: | 2023-03-23 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRegeneron's Dupixent shows promise as COPD treatmentCNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearingCNBC's Meg Tirrell reports on the Senate hearing on drug prices, which featured an exchange between Sen. Bernie Sanders and Moderna CEO Stéphane Bancel.
SVB fallout: The impacts on the biotech sector
  + stars: | 2023-03-13 | by ( Meg Tirrell | ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSVB fallout: The impacts on the biotech sectorCNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew weight loss drugs will help tackle America's obesity epidemic, says Dr. Scott GottliebDr. Scott Gottlieb, former FDA commissioner, and CNBC's Meg Tirrell join 'Power Lunch' to discuss WeightWatchers upcoming telehealth deal, new weight loss drugs coming to market and regulatory considerations associated with long-term medicine use.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWW International CEO on weight loss drugs: Still critical you make the right lifestyle changesCNBC's Meg Tirrell talks with Sima Sistani, WW International CEO, on 'Closing Bell: Overtime' to discuss the company's stock surge after announcing it had acquired Sequence, a telehealth platform that helps treat obesity.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe quality of your clinical data drives everything, says Reata Pharma CEO Warren HuffWarren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsCNBC's Meg Tirrell and David Ricks, Eli Lilly CEO, joins 'Closing Bell: Overtime' to discuss the company's decision to slash insulin prices. He also discusses his economic outlook and the timeline for approval of drugs in its pipeline.
Eli Lilly cuts insulin prices by 70%
  + stars: | 2023-03-01 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly cuts insulin prices by 70%CNBC's Meg Tirrell joins 'The Exchange' to discuss Eli Lilly's decision to set insulin price caps, the motivations behind the company's decision, and whether or not other insulin producers will join them in cutting prices.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisory panel votes in favor of adult RSV vaccine from GSK PLCCNBC's Meg Tirrell joins 'Power Lunch' to discuss GSK PLC's RSV vaccine receiving FDA support, ongoing questions around the drug's approval and the timeline for the drug to be available for children.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAs we work more on the human genome project, the market for rare disease therapies grows, says Nord CEOCNBC's Meg Tirrell, Nord CEO Peter Saltonstall and Boston Children's Hospital's Dr. Olaf Bodamer join 'Power Lunch' to discuss pharmaceutical companies developing treatments for rare disease, the growth expectations for rare disease pharmaceuticals and the state of competition in the rare disease treatment space.
FDA advisers support Pfizer's RSV vaccine for older adults
  + stars: | 2023-02-28 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers support Pfizer's RSV vaccine for older adultsCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA support for a Pfizer RSV vaccine for adults 65 and over.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovavax stock down on concern over whether the company can continueCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Novavax's warning that it may not be able to continue as a company. Also, Sarepta shares rise on FDA signaling no advisory meeting on gene therapy.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna and Merck receive FDA breakthrough status for personalized cancer vaccineCNBC's Meg Tirrell reports on news from Moderna and Merck.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna, Merck receives FDA breakthrough status for personalized cancer vaccineCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Merck and Moderna receiving FDA breakthrough status for a personalized cancer vaccine.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO on safety concerns associated with off-label use of diabetes drugsCNBC's Meg Tirrell joins 'Closing Bell' to report on rapid prescription growth for diabetes medicine, celebrities using Ozempic and Wegovy for weight loss and the safety related to broad use of medicines.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer responds to White House plans to end Covid public health emergencyCNBC's Meg Tirrell joins 'Halftime Report' for a breaking news update regarding the White House decision to end the Covid health emergency this May.
Total: 25